Skip to main content

  • Percutaneous Mitral Valve Repair Vs. Stand-Alone Medical Therapy in Patients with Functional Mitral Regurgitation and Heart Failure

    • Posted: 03/03/2020
    • Author:

      Tomás Benito-González, Rodrigo Estévez-Loureiro, Pedro A. Villablanca, Patrizio Armeni, Ignacio Iglesias-Gárriz, Carlos Minguito, Carmen Garrote, Armando Pérez de Prado, Elena Tundidor-Sanz, Javier Gualis and Felipe Fernández-Vázquez

    • CRM2020

    Highlights

    • Functional mitral regurgitation is a common finding among patients with heart failure and it is related to adverse events
    • Our meta-analysis show a statistically significant reduction in all-cause mortality favoring MitraClip
    • Our data show a significant reduction in heart failure hospitalizations and indication for advanced heart failure therapies
    • Our work supports the use of MitraClip in patients with functional mitral regurgitation and heart failure

    Abstract

    Background

    Functional mitral regurgitation (FMR) is a common finding among patients with heart failure (HF) and it is related to adverse events. Outcomes in patients undergoing transcatheter mitral valve repair (TMVR) are still a matter of debate. We performed a meta-analysis to assess mid- and long-term outcomes of patients with FMR treated with MitraClip® compared to medical management.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details